Evidence map›Paper›PMID 28196983›Full record

ArticleLeukemia2017

Genomic profiling of Acute lymphoblastic leukemia in ataxia telangiectasia patients reveals tight link between ATM mutations and chromothripsis.

M Ratnaparkhe, M Hlevnjak, T Kolb, A Jauch, K K Maass, F Devens, A Rode, V Hovestadt, A Korshunov, A Pastorczak and 28 more

Abstract readComparative Study
PubMed Publisher
In one paragraph

Article in Leukemia, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.

0numbers the graph read from it
0cells of the map it votes in
34citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

34 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Chromothripsis.Methods in molecular biology (Clifton, N.J.) · 2025
    Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Inborn errors of immunity caused by defects in the DNA damage response pathways: Importance of minimizing treatment-related genotoxicity.Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology · 2022
    Review
  15. Review
  16. Insight into the Molecular Basis Underlying Chromothripsis.International journal of molecular sciences · 2022
    Review
  17. Review
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

38 authors.

M RatnaparkheDivision of Molecular Genetics, German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany.
M HlevnjakDivision of Molecular Genetics, German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany.
T KolbDivision of Molecular Genetics, German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany.
A JauchInstitute of Human Genetics, University Heidelberg, Heidelberg, Germany.
K K MaassDivision of Molecular Genetics, German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany.
F DevensDivision of Molecular Genetics, German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany.
A RodeDivision of Molecular Genetics, German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany.
V HovestadtDivision of Molecular Genetics, German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany.
A KorshunovClinical Cooperation Unit Neuropathology, German Cancer Research Center (DKFZ), and Department of Neuropathology University Hospital, Heidelberg, Germany.
A PastorczakDepartment of Pediatrics, Oncology, Hematology and Diabetology, Medical University of Lodz, Lodz, Poland.
W MlynarskiDepartment of Pediatrics, Oncology, Hematology and Diabetology, Medical University of Lodz, Lodz, Poland.
S SungaleeEMBL Heidelberg, Genome Biology, Heidelberg, Germany.
J KorbelEMBL Heidelberg, Genome Biology, Heidelberg, Germany.
J HoellDepartment of Pediatric Oncology, Hematology and Clinical Immunology, Heinrich-Heine-University, Medical Faculty, Düsseldorf, Germany.
U FischerDepartment of Pediatric Oncology, Hematology and Clinical Immunology, Heinrich-Heine-University, Medical Faculty, Düsseldorf, Germany.
T MildeClinical Cooperation Unit Pediatric Oncology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
C KrammDepartment of Pediatric Oncology, University of Halle, Halle, Germany.
M NathrathClinical Cooperation Group Osteosarcoma, Pediatric Oncology Center, Department of Pediatrics, Technical University Munich, Munich, Germany.
K ChrzanowskaDepartment of Medical Genetics, The Children's Memorial Health Institute, Warsaw, Poland.
E TauschDepartment of Internal Medicine III, University of Ulm, Germany.
M TakagiDepartment of Pediatrics and Developmental Biology, Tokyo Medical and Dental University, Tokyo, Japan.ORCID 0000-0002-7580-9184
T TagaDepartment of Pediatrics, Shiga University of Medical Science, Otsu, Japan.
S ConstantiniDepartment of Pediatric Neurosurgery, Dana Children's Hospital, Tel-Aviv Medical Center, Tel-Aviv University, Tel Aviv, Israel.
J LoeffenErasmus Medical Center - Sophia Children's Hospital, Rotterdam, The Netherlands.
J MeijerinkPrincess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.
S ZielenDepartment of Paediatric Pulmonology, Allergy and Cystic Fibrosis, Children's Hospital, Goethe-University, Frankfurt, Germany.
G GohringInstitute of Human Genetics, Hannover Medical School, Hannover, Germany.
B SchlegelbergerInstitute of Human Genetics, Hannover Medical School, Hannover, Germany.
E MaassOlgahospital Stuttgart, Children's Hospital, Klinikum Stuttgart, Stuttgart, Germany.
R SiebertInstitute of Human Genetics, University Hospital Schleswig-Holstein Campus Kiel/Christian-Albrechts University Kiel, Germany.
J KunzDepartment of Pediatric Oncology, Hematology and Immunology, University of Heidelberg, Germany.
A E KulozikDepartment of Pediatric Oncology, Hematology and Immunology, University of Heidelberg, Germany.
B WorstDepartment of Pediatric Oncology, Hematology and Immunology, University of Heidelberg, Germany.
D T JonesDepartment of Pediatric Oncology, Hematology and Immunology, University of Heidelberg, Germany.
S M PfisterDepartment of Pediatric Oncology, Hematology and Immunology, University of Heidelberg, Germany.
M ZapatkaDivision of Molecular Genetics, German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany.ORCID 0000-0001-8287-5967
P LichterDivision of Molecular Genetics, German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany.
A ErnstDivision of Molecular Genetics, German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Recent developments in sequencing technologies led to the discovery of a novel form of genomic instability, termed chromothripsis. This catastrophic genomic event, involved in tumorigenesis, is characterized by tens to hundreds of simultaneously acquired locally clustered rearrangements on one chromosome. We hypothesized that leukemias developing in individuals with Ataxia Telangiectasia, who are born with two mutated copies of the ATM gene, an essential guardian of genome stability, would show a higher prevalence of chromothripsis due to the associated defect in DNA double-strand break repair. Using whole-genome sequencing, fluorescence in situ hybridization and RNA sequencing, we characterized the genomic landscape of Acute Lymphoblastic Leukemia (ALL) arising in patients with Ataxia Telangiectasia. We detected a high frequency of chromothriptic events in these tumors, specifically on acrocentric chromosomes, as compared with tumors from individuals with other types of DNA repair syndromes (27 cases total, 10 with Ataxia Telangiectasia). Our data suggest that the genomic landscape of Ataxia Telangiectasia ALL is clearly distinct from that of sporadic ALL. Mechanistically, short telomeres and compromised DNA damage response in cells of Ataxia Telangiectasia patients may be linked with frequent chromothripsis. Furthermore, we show that ATM loss is associated with increased chromothripsis prevalence in additional tumor entities.

Indexed as

AdolescentAtaxia TelangiectasiaAtaxia Telangiectasia Mutated ProteinsChildChild, PreschoolChromosomes, HumanChromothripsisDNA, NeoplasmDNA RepairFemaleGenome, HumanGenomic InstabilityHumansIn Situ Hybridization, FluorescenceMaleMutationAtaxia Telangiectasia Mutated ProteinsATM protein, humanDNA, NeoplasmNeoplasm ProteinsRNA, Neoplasm

Identifiers

PMID28196983

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.